Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses

Starting soon · Not applicable

Conditions studied: Opioid Use Disorder, Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate

In brief

This study is testing whether offering buprenorphine treatment directly at syringe service programs (SSPs) helps more people start and stay in treatment for opioid use disorder (OUD) than referring them to community buprenorphine treatment providers. Buprenorphine is a medication that helps reduce opioid cravings and withdrawal symptoms. The study compares two ways of connecting people to treatment: Referral to a community treatment provider (usual care before the new program begins). Onsite, low-threshold buprenorphine treatment at the SSP, which allows participants to start medication quickly and without having to establish care at another provider. Participants will be adults who have opioid use disorder and are SSP clients. Each SSP will begin offering the new onsite buprenorphine program at different times during the study. Researchers will collect information before and after the new program begins to see how it affects treatment engagement and health outcomes. The study will also examine how easy or difficult it is for SSPs to start and run the new program, how acceptable it is to staff and participants, and whether it is cost-effective. The overall goal is to find better ways to expand access to life-saving opioid treatment in community-based settings.

Key facts

Study ID

NCT07631598

Run by

Montefiore Medical Center

People needed

512

Starts

2026-08-10

Expected to finish

2028-06-01

Last updated by the study team

2026-06-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• ≥ 18 years old;
• Meet DSM-5 criteria for moderate or severe OUD;
• Interest in receiving buprenorphine treatment;
• Speaks English or Spanish;
• Currently an SSP client at the time of enrollment;
• Ability to provide informed consent.

You may not qualify if…

• Current use of prescribed opioid agonist treatment, as assessed by self-report, at the time of enrollment;
• Unstable mental health or medical condition that requires an immediate clinical evaluation or higher level of care;
• Allergy to buprenorphine;
• Currently detained in jail, prison, residential substance use treatment facility, or other overnight facility as required by court of law. or have pending legal action that could prevent participation on study activities.

Where it is running

• Community Health Project Los Angeles (CHPLA) — Los Angeles, California, United States
• HIPS — Washington D.C., District of Columbia, United States
• CARPBR/Be Safe Syringe Program — Baton Rouge, Louisiana, United States
• Harm Reduction Sisters — Duluth, Minnesota, United States
• Alianza of New Mexico — Roswell, New Mexico, United States
• HIV Alliance — Grants Pass, Oregon, United States
• Challenges, Inc/Prisma Health — Greenville, South Carolina, United States
• Vivent Health — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.